Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Stroke-Pipeline Review, H1 2015

Stroke-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Stroke-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Stroke-Pipeline Review, H1 2015', provides an overview of the Stroke's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Stroke

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Stroke and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Stroke pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Stroke

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Stroke Overview 8

Therapeutics Development 9

Stroke-Therapeutics under Development by Companies 11

Stroke-Therapeutics under Investigation by Universities/Institutes 20

Stroke-Pipeline Products Glance 23

Stroke-Products under Development by Companies 27

Stroke-Products under Investigation by Universities/Institutes 37

Stroke-Companies Involved in Therapeutics Development 40

Stroke-Therapeutics Assessment 127

Drug Profiles 149

Stroke-Recent Pipeline Updates 393

Stroke-Dormant Projects 489

Stroke-Discontinued Products 500

Stroke-Product Development Milestones 505

Appendix 513

List of Tables

Number of Products under Development for Stroke, H1 2015 28

Number of Products under Development for Stroke-Comparative Analysis, H1 2015 29

Number of Products under Development by Companies, H1 2015 31

Number of Products under Development by Companies, H1 2015 (Contd..1) 32

Number of Products under Development by Companies, H1 2015 (Contd..2) 33

Number of Products under Development by Companies, H1 2015 (Contd..3) 34

Number of Products under Development by Companies, H1 2015 (Contd..4) 35

Number of Products under Development by Companies, H1 2015 (Contd..5) 36

Number of Products under Development by Companies, H1 2015 (Contd..6) 37

Number of Products under Development by Companies, H1 2015 (Contd..7) 38

Number of Products under Investigation by Universities/Institutes, H1 2015 39

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 41

Comparative Analysis by Late Stage Development, H1 2015 42

Comparative Analysis by Clinical Stage Development, H1 2015 43

Comparative Analysis by Early Stage Development, H1 2015 44

Comparative Analysis by Unknown Stage Development, H1 2015 45

Products under Development by Companies, H1 2015 46

Products under Development by Companies, H1 2015 (Contd..1) 47

Products under Development by Companies, H1 2015 (Contd..2) 48

Products under Development by Companies, H1 2015 (Contd..3) 49

Products under Development by Companies, H1 2015 (Contd..4) 50

Products under Development by Companies, H1 2015 (Contd..5) 51

Products under Development by Companies, H1 2015 (Contd..6) 52

Products under Development by Companies, H1 2015 (Contd..7) 53

Products under Development by Companies, H1 2015 (Contd..8) 54

Products under Development by Companies, H1 2015 (Contd..9) 55

Products under Investigation by Universities/Institutes, H1 2015 56

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 57

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 58

Stroke-Pipeline by AB Science, H1 2015 59

Stroke-Pipeline by Acorda Therapeutics, Inc., H1 2015 60

Stroke-Pipeline by Acticor Biotech, H1 2015 61

Stroke-Pipeline by advanceCor GmbH, H1 2015 62

Stroke-Pipeline by Affibody AB, H1 2015 63

Stroke-Pipeline by AGY Therapeutics, Inc., H1 2015 64

Stroke-Pipeline by Anavex Life Sciences Corp., H1 2015 65

Stroke-Pipeline by Angion Biomedica Corp., H1 2015 66

Stroke-Pipeline by Apceth GmbH & Co. KG, H1 2015 67

Stroke-Pipeline by APT Therapeutics, Inc., H1 2015 68

Stroke-Pipeline by ArmaGen Technologies, Inc., H1 2015 69

Stroke-Pipeline by AstraZeneca Plc, H1 2015 70

Stroke-Pipeline by Athersys, Inc., H1 2015 71

Stroke-Pipeline by Bayer AG, H1 2015 72

Stroke-Pipeline by biOasis Technologies Inc., H1 2015 73

Stroke-Pipeline by Biogen, Inc., H1 2015 74

Stroke-Pipeline by BioTime, Inc., H1 2015 75

Stroke-Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 76

Stroke-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 77

Stroke-Pipeline by Cetazam Therapeutics LLC, H1 2015 78

Stroke-Pipeline by CHA Bio & Diostech Co., Ltd., H1 2015 79

Stroke-Pipeline by CoDa Therapeutics, Inc., H1 2015 80

Stroke-Pipeline by Concert Pharmaceuticals, Inc., H1 2015 81

Stroke-Pipeline by D-Pharm Ltd., H1 2015 82

Stroke-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 83

Stroke-Pipeline by DiaMedica Inc., H1 2015 84

Stroke-Pipeline by Digna Biotech, S.L., H1 2015 85

Stroke-Pipeline by Dong Wha Pharma Co., Ltd., H1 2015 86

Stroke-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 87

Stroke-Pipeline by Fina Biotech, H1 2015 88

Stroke-Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 89

Stroke-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2015 90

Stroke-Pipeline by Georgia Tech Research Corporation, H1 2015 91

Stroke-Pipeline by Glucox Biotech AB, H1 2015 92

Stroke-Pipeline by Green Cross Corporation, H1 2015 93

Stroke-Pipeline by Grifols, S.A., H1 2015 94

Stroke-Pipeline by Huons Co., Ltd., H1 2015 95

Stroke-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 96

Stroke-Pipeline by International Stem Cell Corporation, H1 2015 97

Stroke-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 98

Stroke-Pipeline by JN-International Medical Corporation, H1 2015 99

Stroke-Pipeline by Kolon Life Science, Inc., H1 2015 100

Stroke-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 101

Stroke-Pipeline by Lacer, S.A., H1 2015 102

Stroke-Pipeline by LegoChem Biosciences, Inc, H1 2015 103

Stroke-Pipeline by Living Cell Technologies Limited, H1 2015 104

Stroke-Pipeline by Lumosa Therapeutics Co., Ltd., H1 2015 105

Stroke-Pipeline by Mapreg S.A.S., H1 2015 106

Stroke-Pipeline by Mast Therapeutics, Inc., H1 2015 107

Stroke-Pipeline by Medestea Research & Production S.p.A., H1 2015 108

Stroke-Pipeline by MediaPharma s.r.l., H1 2015 109

Stroke-Pipeline by Mesoblast Limited, H1 2015 110

Stroke-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 111

Stroke-Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 112

Stroke-Pipeline by Neuralstem, Inc., H1 2015 113

Stroke-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 114

Stroke-Pipeline by Neuronax SAS, H1 2015 115

Stroke-Pipeline by Neurotec Pharma SL, H1 2015 116

Stroke-Pipeline by NeuroVive Pharmaceutical AB, H1 2015 117

Stroke-Pipeline by New Haven Pharmaceuticals, Inc., H1 2015 118

Stroke-Pipeline by Omeros Corporation, H1 2015 119

Stroke-Pipeline by Orion Oyj, H1 2015 120

Stroke-Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 121

Stroke-Pipeline by Pharmicell Co., Ltd., H1 2015 122

Stroke-Pipeline by Phoenix Biotechnology, Inc., H1 2015 123

Stroke-Pipeline by Phylogica Limited, H1 2015 124

Stroke-Pipeline by PhytoHealth Corporation, H1 2015 125

Stroke-Pipeline by Pozen, Inc., H1 2015 126

Stroke-Pipeline by Q Therapeutics, Inc., H1 2015 127

Stroke-Pipeline by ReCyte Therapeutics, Inc., H1 2015 128

Stroke-Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 129

Stroke-Pipeline by Remedy Pharmaceuticals, Inc., H1 2015 130

Stroke-Pipeline by ReNeuron Group Plc, H1 2015 131

Stroke-Pipeline by Sagene Pharmaceuticals, Inc., H1 2015 132

Stroke-Pipeline by SanBio, Inc., H1 2015 133

Stroke-Pipeline by Saneron CCEL Therapeutics, Inc., H1 2015 134

Stroke-Pipeline by Simcere Pharmaceutical Group, H1 2015 135

Stroke-Pipeline by StemCells, Inc., H1 2015 136

Stroke-Pipeline by Stemedica Cell Technologies, Inc., H1 2015 137

Stroke-Pipeline by Stempeutics Research Private Limited, H1 2015 138

Stroke-Pipeline by SynZyme Technologies, LLC, H1 2015 139

Stroke-Pipeline by Targazyme, Inc., H1 2015 140

Stroke-Pipeline by TikoMed AB, H1 2015 141

Stroke-Pipeline by Vicore Pharma AB, H1 2015 142

Stroke-Pipeline by Virogenomics, Inc., H1 2015 143

Stroke-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 144

Stroke-Pipeline by Xigen SA, H1 2015 145

Assessment by Monotherapy Products, H1 2015 146

Assessment by Combination Products, H1 2015 147

Number of Products by Stage and Target, H1 2015 149

Number of Products by Stage and Mechanism of Action, H1 2015 157

Number of Products by Stage and Route of Administration, H1 2015 164

Number of Products by Stage and Molecule Type, H1 2015 166

Stroke Therapeutics-Recent Pipeline Updates, H1 2015 411

Stroke-Dormant Projects, H1 2015 507

Stroke-Dormant Projects (Contd..1), H1 2015 508

Stroke-Dormant Projects (Contd..2), H1 2015 509

Stroke-Dormant Projects (Contd..3), H1 2015 510

Stroke-Dormant Projects (Contd..4), H1 2015 511

Stroke-Dormant Projects (Contd..5), H1 2015 512

Stroke-Dormant Projects (Contd..6), H1 2015 513

Stroke-Dormant Projects (Contd..7), H1 2015 514

Stroke-Dormant Projects (Contd..8), H1 2015 515

Stroke-Dormant Projects (Contd..9), H1 2015 516

Stroke-Dormant Projects (Contd..10), H1 2015 517

Stroke-Discontinued Products, H1 2015 518

Stroke-Discontinued Products (Contd..1), H1 2015 519

Stroke-Discontinued Products (Contd..2), H1 2015 520

Stroke-Discontinued Products (Contd..3), H1 2015 521

Stroke-Discontinued Products (Contd..4), H1 2015 522

List of Figures

Number of Products under Development for Stroke, H1 2015 28

Number of Products under Development for Stroke-Comparative Analysis, H1 2015 29

Number of Products under Development by Companies, H1 2015 30

Number of Products under Investigation by Universities/Institutes, H1 2015 39

Comparative Analysis by Late Stage Development, H1 2015 42

Comparative Analysis by Clinical Stage Development, H1 2015 43

Comparative Analysis by Early Stage Products, H1 2015 44

Assessment by Monotherapy Products, H1 2015 146

Number of Products by Top 10 Targets, H1 2015 148

Number of Products by Stage and Top 10 Targets, H1 2015 148

Number of Products by Top 10 Mechanism of Actions, H1 2015 156

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 156

Number of Products by Top 10 Routes of Administration, H1 2015 163

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 163

Number of Products by Top 10 Molecule Types, H1 2015 165

Number of Products by Stage and Top 10 Molecule Types, H1 2015 165

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science

Acorda Therapeutics, Inc.

Acticor Biotech

advanceCor GmbH

Affibody AB

AGY Therapeutics, Inc.

Anavex Life Sciences Corp.

Angion Biomedica Corp.

Apceth GmbH & Co. KG

APT Therapeutics, Inc.

ArmaGen Technologies, Inc.

AstraZeneca Plc

Athersys, Inc.

Bayer AG

biOasis Technologies Inc.

Biogen, Inc.

BioTime, Inc.

Cardax Pharmaceuticals, Inc.

Cellular Biomedicine Group, Inc.

Cetazam Therapeutics LLC

CHA Bio & Diostech Co., Ltd.

CoDa Therapeutics, Inc.

Concert Pharmaceuticals, Inc.

D-Pharm Ltd.

Daiichi Sankyo Company, Limited

DiaMedica Inc.

Digna Biotech, S.L.

Dong Wha Pharma Co., Ltd.

F. Hoffmann-La Roche Ltd.

Fina Biotech

Generon (Shanghai) Corporation Ltd.

Genervon Biopharmaceuticals, LLC

Georgia Tech Research Corporation

Glucox Biotech AB

Green Cross Corporation

Grifols, S.A.

Huons Co., Ltd.

Inbiopro Solutions Pvt. Ltd.

International Stem Cell Corporation

Jeil Pharmaceutical Co., Ltd.

JN-International Medical Corporation

Kolon Life Science, Inc.

Laboratoires Pierre Fabre SA

Lacer, S.A.

LegoChem Biosciences, Inc

Living Cell Technologies Limited

Lumosa Therapeutics Co., Ltd.

Mapreg S.A.S.

Mast Therapeutics, Inc.

Medestea Research & Production S.p.A.

MediaPharma s.r.l.

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

Mnemosyne Pharmaceuticals, Inc.

Neuralstem, Inc.

Neuren Pharmaceuticals Limited

Neuronax SAS

Neurotec Pharma SL

NeuroVive Pharmaceutical AB

New Haven Pharmaceuticals, Inc.

Omeros Corporation

Orion Oyj

Panacea Pharmaceuticals, Inc.

Pharmicell Co., Ltd.

Phoenix Biotechnology, Inc.

Phylogica Limited

PhytoHealth Corporation

Pozen, Inc.

Q Therapeutics, Inc.

ReCyte Therapeutics, Inc.

RegeneRx Biopharmaceuticals, Inc.

Remedy Pharmaceuticals, Inc.

ReNeuron Group Plc

Sagene Pharmaceuticals, Inc.

SanBio, Inc.

Saneron CCEL Therapeutics, Inc.

Simcere Pharmaceutical Group

StemCells, Inc.

Stemedica Cell Technologies, Inc.

Stempeutics Research Private Limited

SynZyme Technologies, LLC

Targazyme, Inc.

TikoMed AB

Vicore Pharma AB

Virogenomics, Inc.

WhanIn Pharmaceutical Co., Ltd.

Xigen SA

Stroke Therapeutic Products under Development, Key Players in Stroke Therapeutics, Stroke Pipeline Overview, Stroke Pipeline, Stroke Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com